Investment Analysts’ Updated EPS Estimates for February, 14th (AF, AFX, AZN, CNO, CTEC, DAI, DB1, DCC, EZJ, GBG)

Investment Analysts’ updated eps estimates for Thursday, February 14th:

Air France KLM (EPA:AF) was given a €10.50 ($12.21) price target by analysts at Royal Bank of Canada. The firm currently has a neutral rating on the stock.

Carl Zeiss Meditec (ETR:AFX) was given a €80.00 ($93.02) target price by analysts at HSBC Holdings plc. The firm currently has a neutral rating on the stock.

AstraZeneca (LON:AZN) had its buy rating reaffirmed by analysts at Shore Capital.

AstraZeneca (LON:AZN) had its hold rating reaffirmed by analysts at Liberum Capital.

CNO Financial Group (NYSE:CNO) had its hold rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $21.00 target price on the stock.

ConvaTec Group (LON:CTEC) had its hold rating reaffirmed by analysts at Peel Hunt.

Daimler (ETR:DAI) was given a €80.00 ($93.02) price target by analysts at Deutsche Bank AG. The firm currently has a buy rating on the stock.

Deutsche Boerse (ETR:DB1) was given a €125.00 ($145.35) price target by analysts at Royal Bank of Canada. The firm currently has a neutral rating on the stock.

DCC (LON:DCC) had its buy rating reaffirmed by analysts at UBS Group AG.

easyJet (LON:EZJ) had its hold rating reissued by analysts at Liberum Capital.

GB Group (LON:GBG) had its price target increased by Peel Hunt from GBX 600 ($7.84) to GBX 626 ($8.18). The firm currently has a buy rating on the stock.

MJ Gleeson (LON:GLE) had its price target raised by Peel Hunt from GBX 630 ($8.23) to GBX 715 ($9.34). They currently have a hold rating on the stock.

Intercontinental Hotels Group (LON:IHG) was upgraded by analysts at UBS Group AG to a neutral rating.

Impax Asset Management Group (LON:IPX) had its buy rating reaffirmed by analysts at Peel Hunt.

Jenoptik (ETR:JEN) was given a €30.00 ($34.88) price target by analysts at HSBC Holdings plc. The firm currently has a neutral rating on the stock.

Kelly Services (NASDAQ:KELYA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $27.00 price target on the stock. According to Zacks, “Kelly Services, Inc. is a global leader of providing workforce solutions. Kelly Services, Inc. and its subsidiaries, offer a comprehensive array of outsourcing and consulting services as well as world-class staffing on a temporary, temporary-to-hire, and direct-hire basis. The company provides temporary office clerical, marketing, professional, technical, light industrial, home care services, management services and other business services to a diversified group of customers through offices located in major cities of the United States, Australia, Canada, Denmark, France, Ireland, Italy, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Russia, Spain, Switzerland and United Kingdom. Kelly Temporary Services provides office clerical, marketing, professional, technical, semi-skilled light industrial and management services. “

Keysight Technologies (NYSE:KEYS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $88.00 price target on the stock. According to Zacks, “Keysight Technologies, Inc. is an Applied Technology company that provides electronic measurement solutions to the communications and electronics industries. It provides electronic measurement instruments and systems and related software, software design tools, and related services that are used in the design, development, manufacture, installation, deployment, and operation of electronics equipment. The Company provides start-up assistance, consulting, optimization and application support throughout the customer’s product lifecycle. It also offers customization, consulting and optimization services throughout the customer’s product lifecycle. Keysight Technologies, Inc. is headquartered in Santa Rosa, California. “

Kamada (NASDAQ:KMDA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $6.25 price target on the stock. According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

KT (NYSE:KT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $15.00 price target on the stock. According to Zacks, “KT Corporation provides telecommunication services. Its services include mobile telecommunications services, telephone services, fixed-line and VoIP telephone services. The Company also provides interconnection services to other telecommunications companies, broadband Internet access services and other Internet-related services. It also offers information technology and network services, including consulting, designing, building, and maintaining of systems and communication networks. KT Corporation, formerly known as Korea Telecom Corp., is headquartered in Sungnam, South Korea. “

Ladder Capital (NYSE:LADR) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ladder Capital Corp is a commercial real estate finance company. The Company operates in three segments: Loans, Securities and Real Estate. It focused on midmarket senior secured commercial real estate first mortgage loans, investment grade-rated securities secured by first mortgage loans on commercial real estate and investing in net leased and other commercial real estate. The company also provides services of the commercial real estate industry which includes origination, credit, underwriting, structuring, capital markets and asset management. Ladder Capital Corp is headquartered in New York City. “

Lantheus (NASDAQ:LNTH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $20.00 target price on the stock. According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

LogicBio Therapeutics (NASDAQ:LOGC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company’s technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. “

Lancashire (LON:LRE) had its under review rating reiterated by analysts at Shore Capital.

Lancashire (LON:LRE) had its add rating reiterated by analysts at Peel Hunt.

Lattice Semiconductor (NASDAQ:LSCC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Lattice Semiconductor Corporation designs, develops and markets high performance programmable logic devices and related development system software. Programmable logic devices are standard smiconductor components that can be configured by the end customer as specific logic functions, enabling shorter design cycle times and reduced developpment costs. “

Live Nation Entertainment (NYSE:LYV) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $63.00 target price on the stock. According to Zacks, “Live Nation Entertainment, Inc. is the world’s premier live entertainment company, consisting of Live Nation, Ticketmaster and Front Line Management Group. The Company engages in producing, marketing, and selling live concerts for artists via its concert pipe. Live Nation owns and operates many venues, including House of Blues music venues and locations, such as The Fillmore in San Francisco, Nikon at Jones Beach Theatre in New York and London’s Wembley Arena. In addition, it also produces, promotes or hosts theatrical, specialized motor sports and other live entertainment events. The Company is driving major innovations in ticketing technology, marketing and service. It offers ticket sales, ticket resale services, and marketing and distribution through ticketmaster.com, an e-commerce site on the Internet. Live Nation Entertainment, Inc. was formerly known as Live Nation, Inc. and is based in Beverly Hills, California. “

MARKS & SPENCER/S (OTCMKTS:MAKSY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “MARKS & SPENCER is one of the UK’s leading retailers, offering high quality, great value clothing, as well as home products and outstanding quality food. M&S employs over 75,000 people and has over 600 stores in the UK and over 275 stores in 39 territories around the world. “

Matson (NYSE:MATX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Matson, Inc. operates as an ocean transportation and logistics company. It offers shipping services in Hawaii, Guam, and Micronesia islands and expedited service from China to southern California. The company’s logistics services consist of rail intermodal service, long haul and regional highway truckload services, less-than-truckload transportation, specialized hauling, flatbed, and project works, warehousing and distribution services, transloading, cross-dock services, and packaging services, and network analysis and freight management services. Matson, Inc., formerly known as Alexander & Baldwin Holdings, Inc., is headquartered in Honolulu, Hawaii. “

Moleculin Biotech (NASDAQ:MBRX) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company’s lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX. “

Mongodb (NASDAQ:MDB) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “MongoDB, Inc. provides general purpose database platform. Its products include MongoDB Enterprise Advanced, MongoDB Enterprise for OEM, MongoDB Professional, MongoDB Stitch, MongoDB Atlas, Development Support, Ops Manager, Cloud Manager, Compass, Connector for business intelligence, and Connector for Spark. The company serves financial services, government, healthcare, media and entertainment, retail, technology and telecommunications industries. MongoDB, Inc. is headquartered in New York. “

MICHELIN COMPAG/ADR (OTCMKTS:MGDDY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Compagnie Generale des Etablissements Michelin manufactures and sells tires for all kinds of vehicles, publishes maps and guides and operates a number of digital services. It manufactures and sells tires for cars, two-wheel vehicles, trucks, construction machinery, tractors and aircrafts. It also sells various car and bicycle accessories like pumps, manometers bicycle helmets, hubcaps, replacement components for tires and transport accessories. Other products sold by the company include protective clothing, table tennis rackets, shoe insoles along with many other items designed for road users. Compagnie Generale des Etablissements Michelin is based in Clermont-Ferrand, France. “

Melinta Therapeutics (NASDAQ:MLNT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta’s lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. “

Marcus & Millichap (NYSE:MMI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Marcus & Millichap, Inc. operates a brokerage firm specializing in real estate investments. It offers commercial real estate investment brokerage services for multifamily, retail, office, industrial, land, self-storage, seniors housing, manufactured housing, and mixed-use/other property types. The company also provides a range of advisory and consulting services to developers, lenders, owners, real estate investment trusts, high net worth individuals, pension fund advisors, and other institutions. Marcus & Millichap, Inc. is based in Calabasas, California. “

Menlo Therapeutics (NASDAQ:MNLO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company’s product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. “

Moneysupermarket.Com Group (LON:MONY) had its hold rating reiterated by analysts at Shore Capital.

Moneysupermarket.Com Group (LON:MONY) had its buy rating reissued by analysts at Liberum Capital.

Motif Bio (LON:MTFB) had its under review rating reiterated by analysts at Peel Hunt.

NCS Multistage (NASDAQ:NCSM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “NCS Multistage Holdings, Inc. provides engineered products and support services for oil and natural gas well completions and field development strategies primarily in the United States and internationally. NCS Multistage Holdings Inc. is headquartered in Houston, Texas. “

Nestlé (VTX:NESN) was given a CHF 92 target price by analysts at Baader Bank. The firm currently has a buy rating on the stock.

Oracle (NYSE:ORCL) was given a $55.00 price target by analysts at Goldman Sachs Group Inc. The firm currently has a buy rating on the stock.

PureTech Health (LON:PRTC) had its buy rating reiterated by analysts at Peel Hunt.

PureTech Health (LON:PRTC) had its buy rating reissued by analysts at Liberum Capital.

Restaurant Group (LON:RTN) had its hold rating reiterated by analysts at Liberum Capital.

Restaurant Group (LON:RTN) had its buy rating reaffirmed by analysts at Shore Capital.

Restaurant Group (LON:RTN) had its hold rating reaffirmed by analysts at Peel Hunt.

Safestore (LON:SAFE) had its hold rating reiterated by analysts at Peel Hunt.

Safestore (LON:SAFE) had its buy rating reaffirmed by analysts at Liberum Capital.

SOCO International (LON:SIA) had its add rating reissued by analysts at Peel Hunt.

SimiGon (LON:SIM) had its under review rating reiterated by analysts at FinnCap.

Trifast (LON:TRI) had its corporate rating reissued by analysts at FinnCap.

Wandisco (LON:WAND) had its buy rating reissued by analysts at Peel Hunt.

Whitbread (LON:WTB) had its neutral rating reiterated by analysts at UBS Group AG.

Receive News & Ratings for Air France KLM SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Air France KLM SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply